Khuda Khan
Hematology & Oncology · Louisville, KYNPI 1619946159
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $269,990 of the $359,065 with a category attached, or 75.2%. 21 manufacturers reported payments, led by AstraZeneca at 34.5% of the total. Reporting peaked in 2019 at $81,120 and has fallen 64.0% since, to $29,205 in 2025. Among hematology & oncology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 378 payments — averaging $949.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$124K
- Genentech USA, Inc.$112K
- Johnson & Johnson$68K
- Novartis$30K
- Sanofi$15K
- Eisai Inc.$8K
- plus $2K from 15 others
Across 5 payments — averaging $674.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$3K
What the payments were for
- Consulting fees$29,8938%
- Speaking & faculty fees$269,99075%
- Travel & lodging$45,66113%
- Food & beverage$13,3074%
- Education$2140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 141 | $123,969 |
| Genentech USA, Inc. | 86 | $111,740 |
| Johnson & Johnson(2 entities) | 69 | $68,200 |
| Novartis | 23 | $29,804 |
| Sanofi | 12 | $15,140 |
| Eisai Inc. | 11 | $8,411 |
| Abbott | 7 | $861 |
| Pfizer | 4 | $148 |
| Beone Medicines USA, Inc. | 1 | $125 |
| Geron Corporation | 1 | $120 |
| Merck | 7 | $119 |
| AbbVie | 2 | $109 |
| Astellas Pharma US Inc | 5 | $88 |
| Ipsen Biopharmaceuticals, Inc | 1 | $88 |
| E.r. Squibb & Sons, L.L.C. | 1 | $35 |
| Amgen | 2 | $28 |
| Beigene USA, Inc. | 1 | $25 |
| Bristol Myers Squibb | 1 | $15 |
| Morphosys, US Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Venclexta$74,955
- DARZALEX$65,950
- ULTOMIRIS$41,453
- Lunsumio$22,278
- POLIVY$19,562
- Rituxan$19,044
- GAZYVA$19,044
- GLEEVEC$15,661
- WAYRILZ$14,447
- TASIGNA$10,563
- SOLIRIS$9,521
- Columvi$8,809
- LENVIMA$8,154
- TECVAYLI$1,100
- CABLIVI$392
- ENJAYMO$270
- Diamondback Coronary$268
- DRAGONFLY OPSTAR$174
- COROFLOW$154
- Xience V coronary stent system$127
How this compares
$359,065 in reported general payments places this provider in the 95th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 47 | $955,162 |
| RevlimidLenalidomide | 48 | $783,589 |
| BrukinsaZanubrutinib | 51 | $656,853 |
| ImbruvicaIbrutinib | 21 | $318,894 |
| SprycelDasatinib | 20 | $295,916 |
| BosulifBosutinib | 11 | $203,300 |
| CalquenceAcalabrutinib Maleate | 12 | $186,223 |
| EliquisApixaban | 194 | $160,504 |
| XareltoRivaroxaban | 71 | $54,077 |
| Imatinib Mesylate | 25 | $5,637 |
| Fentanyl | 22 | $2,916 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 147 | $2,910 |
| Ondansetron Hcl | 84 | $2,359 |
| Entecavir | 12 | $1,903 |
| Hydroxyurea | 40 | $1,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $35 | $1,251,07867 claims |
| Bristol Myers SquibbRevlimid | $15 | $783,58948 claims |
| Beigene USA, Inc.Brukinsa | $25 | $656,85351 claims |
| PfizerBosulif, Eliquis | $148 | $363,804205 claims |
| AstraZenecaCalquence | $123,969 | $186,22312 claims |
| Johnson & JohnsonXarelto | $68,200 | $54,07771 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $14 | $80075 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 143 hematology & oncology providers in Kentucky.
Other hematology & oncology in Louisville
- Vivek SharmaLouisville$647K
- Goetz KloeckerLouisville$584K
- Jeffrey HargisLouisville$450K
- Mohamed HegaziLouisville$380K
- Jaspreet GrewalLouisville$280K
- Laila AgrawalLouisville$95K
- Brian DongLouisville$31K
- Rohit KumarLouisville$31K
- Vikas SinghLouisville$28K
- Adam LyeLouisville$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.